A citation-based method for searching scientific literature

Daniel W Lee, Rebecca Gardner, David L Porter, Chrystal U Louis, Nabil Ahmed, Michael Jensen, Stephan A Grupp, Crystal L Mackall. Blood 2014
Times Cited: 1411







List of co-cited articles
698 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
41

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Sattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, William Wierda, Cristina Gutierrez, Frederick L Locke, Krishna V Komanduri, Yi Lin, Nitin Jain, Naval Daver,[...]. Nat Rev Clin Oncol 2018
984
32

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Shannon L Maude, Theodore W Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R Verneris, Heather E Stefanski, Gary D Myers,[...]. N Engl J Med 2018
29

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Daniel W Lee, Bianca D Santomasso, Frederick L Locke, Armin Ghobadi, Cameron J Turtle, Jennifer N Brudno, Marcela V Maus, Jae H Park, Elena Mead, Steven Pavletic,[...]. Biol Blood Marrow Transplant 2019
779
29

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
27

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman,[...]. Lancet Oncol 2019
747
24

Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L Maude, Noelle Frey, Pamela A Shaw, Richard Aplenc, David M Barrett, Nancy J Bunin, Anne Chew, Vanessa E Gonzalez, Zhaohui Zheng, Simon F Lacey,[...]. N Engl J Med 2014
23

Cytokine release syndrome.
Alexander Shimabukuro-Vornhagen, Philipp Gödel, Marion Subklewe, Hans Joachim Stemmler, Hans Anton Schlößer, Max Schlaak, Matthias Kochanek, Boris Böll, Michael S von Bergwelt-Baildon. J Immunother Cancer 2018
582
22

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
Jae H Park, Isabelle Rivière, Mithat Gonen, Xiuyan Wang, Brigitte Sénéchal, Kevin J Curran, Craig Sauter, Yongzeng Wang, Bianca Santomasso, Elena Mead,[...]. N Engl J Med 2018
19

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.
Margherita Norelli, Barbara Camisa, Giulia Barbiera, Laura Falcone, Ayurzana Purevdorj, Marco Genua, Francesca Sanvito, Maurilio Ponzoni, Claudio Doglioni, Patrizia Cristofori,[...]. Nat Med 2018
585
19

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.
Juliane Gust, Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, David Myerson, Luis F Gonzalez-Cuyar, Cecilia Yeung, W Conrad Liles, Mark Wurfel, Jose A Lopez,[...]. Cancer Discov 2017
597
18

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Marco L Davila, Isabelle Riviere, Xiuyan Wang, Shirley Bartido, Jae Park, Kevin Curran, Stephen S Chung, Jolanta Stefanski, Oriana Borquez-Ojeda, Malgorzata Olszewska,[...]. Sci Transl Med 2014
18

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Bianca D Santomasso, Jae H Park, Darin Salloum, Isabelle Riviere, Jessica Flynn, Elena Mead, Elizabeth Halton, Xiuyan Wang, Brigitte Senechal, Terence Purdon,[...]. Cancer Discov 2018
338
17

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew A Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G Maloney, Charalambos Andreadis,[...]. Lancet 2020
324
17

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Daniel W Lee, James N Kochenderfer, Maryalice Stetler-Stevenson, Yongzhi K Cui, Cindy Delbrook, Steven A Feldman, Terry J Fry, Rimas Orentas, Marianna Sabatino, Nirali N Shah,[...]. Lancet 2015
15

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.
David T Teachey, Simon F Lacey, Pamela A Shaw, J Joseph Melenhorst, Shannon L Maude, Noelle Frey, Edward Pequignot, Vanessa E Gonzalez, Fang Chen, Jeffrey Finklestein,[...]. Cancer Discov 2016
544
14

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, Juliane Gust, W Conrad Liles, Mark M Wurfel, José A López, Junmei Chen, Dominic Chung, Susanna Harju-Baker,[...]. Blood 2017
479
14


CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.
Theodoros Giavridis, Sjoukje J C van der Stegen, Justin Eyquem, Mohamad Hamieh, Alessandra Piersigilli, Michel Sadelain. Nat Med 2018
500
14

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn,[...]. N Engl J Med 2020
402
14

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
Cameron J Turtle, Laïla-Aïcha Hanafi, Carolina Berger, Theodore A Gooley, Sindhu Cherian, Michael Hudecek, Daniel Sommermeyer, Katherine Melville, Barbara Pender, Tanya M Budiarto,[...]. J Clin Invest 2016
13

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
Stephan A Grupp, Michael Kalos, David Barrett, Richard Aplenc, David L Porter, Susan R Rheingold, David T Teachey, Anne Chew, Bernd Hauck, J Fraser Wright,[...]. N Engl J Med 2013
12

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Noopur Raje, Jesus Berdeja, Yi Lin, David Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Ashley Turka,[...]. N Engl J Med 2019
617
12

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Stephen J Schuster, Jakub Svoboda, Elise A Chong, Sunita D Nasta, Anthony R Mato, Özlem Anak, Jennifer L Brogdon, Iulian Pruteanu-Malinici, Vijay Bhoj, Daniel Landsburg,[...]. N Engl J Med 2017
878
12


Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.
David L Porter, Wei-Ting Hwang, Noelle V Frey, Simon F Lacey, Pamela A Shaw, Alison W Loren, Adam Bagg, Katherine T Marcucci, Angela Shen, Vanessa Gonzalez,[...]. Sci Transl Med 2015
10

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.
Marcela V Maus, Sara Alexander, Michael R Bishop, Jennifer N Brudno, Colleen Callahan, Marco L Davila, Claudia Diamonte, Jorg Dietrich, Julie C Fitzgerald, Matthew J Frigault,[...]. J Immunother Cancer 2020
65
15

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Jennifer N Brudno, Irina Maric, Steven D Hartman, Jeremy J Rose, Michael Wang, Norris Lam, Maryalice Stetler-Stevenson, Dalia Salem, Constance Yuan, Steven Pavletic,[...]. J Clin Oncol 2018
351
10

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.
Michael Kalos, Bruce L Levine, David L Porter, Sharyn Katz, Stephan A Grupp, Adam Bagg, Carl H June. Sci Transl Med 2011
10

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Cameron J Turtle, Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, Sindhu Cherian, Xueyan Chen, Brent Wood, Arletta Lozanski, John C Byrd, Shelly Heimfeld,[...]. J Clin Oncol 2017
373
9

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
Rosalie M Sterner, Reona Sakemura, Michelle J Cox, Nan Yang, Roman H Khadka, Cynthia L Forsman, Michael J Hansen, Fang Jin, Katayoun Ayasoufi, Mehrdad Hefazi,[...]. Blood 2019
225
9

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
Nirali N Shah, Steven L Highfill, Haneen Shalabi, Bonnie Yates, Jianjian Jin, Pamela L Wolters, Amanda Ombrello, Seth M Steinberg, Staci Martin, Cindy Delbrook,[...]. J Clin Oncol 2020
120
9

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
Cameron J Turtle, Laïla-Aïcha Hanafi, Carolina Berger, Michael Hudecek, Barbara Pender, Emily Robinson, Reed Hawkins, Colette Chaney, Sindhu Cherian, Xueyan Chen,[...]. Sci Transl Med 2016
589
9

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Max S Topp, Nicola Gökbuget, Anthony S Stein, Gerhard Zugmaier, Susan O'Brien, Ralf C Bargou, Hervé Dombret, Adele K Fielding, Leonard Heffner, Richard A Larson,[...]. Lancet Oncol 2015
752
9

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
Robert Q Le, Liang Li, Weishi Yuan, Stacy S Shord, Lei Nie, Bahru A Habtemariam, Donna Przepiorka, Ann T Farrell, Richard Pazdur. Oncologist 2018
398
8

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies.
Kevin R Parker, Denis Migliorini, Eric Perkey, Kathryn E Yost, Aparna Bhaduri, Puneet Bagga, Mohammad Haris, Neil E Wilson, Fang Liu, Khatuna Gabunia,[...]. Cell 2020
100
8

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
James N Kochenderfer, Mark E Dudley, Sadik H Kassim, Robert P T Somerville, Robert O Carpenter, Maryalice Stetler-Stevenson, James C Yang, Giao Q Phan, Marybeth S Hughes, Richard M Sherry,[...]. J Clin Oncol 2015
8

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.
David Porter, Noelle Frey, Patricia A Wood, Yanqiu Weng, Stephan A Grupp. J Hematol Oncol 2018
213
8

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
James N Kochenderfer, Mark E Dudley, Steven A Feldman, Wyndham H Wilson, David E Spaner, Irina Maric, Maryalice Stetler-Stevenson, Giao Q Phan, Marybeth S Hughes, Richard M Sherry,[...]. Blood 2012
8

Managing cytokine release syndrome associated with novel T cell-engaging therapies.
Shannon L Maude, David Barrett, David T Teachey, Stephan A Grupp. Cancer J 2014
449
8

The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma.
Jianshu Wei, Yang Liu, Chunmeng Wang, Yajing Zhang, Chuan Tong, Guanghai Dai, Wei Wang, John E J Rasko, J Joseph Melenhorst, Wenbin Qian,[...]. Signal Transduct Target Ther 2020
37
21

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
Frederick L Locke, Sattva S Neelapu, Nancy L Bartlett, Tanya Siddiqi, Julio C Chavez, Chitra M Hosing, Armin Ghobadi, Lihua E Budde, Adrian Bot, John M Rossi,[...]. Mol Ther 2017
337
8



Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma.
Paolo Strati, Sairah Ahmed, Partow Kebriaei, Loretta J Nastoupil, Catherine M Claussen, Grace Watson, Sandra B Horowitz, Anne Rain T Brown, Bryan Do, Maria A Rodriguez,[...]. Blood Adv 2020
50
14

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.
Renier J Brentjens, Marco L Davila, Isabelle Riviere, Jae Park, Xiuyan Wang, Lindsay G Cowell, Shirley Bartido, Jolanta Stefanski, Clare Taylor, Malgorzata Olszewska,[...]. Sci Transl Med 2013
7

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.
David T Teachey, Susan R Rheingold, Shannon L Maude, Gerhard Zugmaier, David M Barrett, Alix E Seif, Kim E Nichols, Erica K Suppa, Michael Kalos, Robert A Berg,[...]. Blood 2013
387
7

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.
John Maher, Renier J Brentjens, Gertrude Gunset, Isabelle Rivière, Michel Sadelain. Nat Biotechnol 2002
608
7

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.
Katrin Mestermann, Theodoros Giavridis, Justus Weber, Julian Rydzek, Silke Frenz, Thomas Nerreter, Andreas Mades, Michel Sadelain, Hermann Einsele, Michael Hudecek. Sci Transl Med 2019
159
7

Managing the toxicities of CAR T-cell therapy.
Sattva S Neelapu. Hematol Oncol 2019
117
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.